Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | type A flavoprotein, putative | 0.0251 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0655 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0655 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0655 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0251 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0251 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0655 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0655 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0251 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0655 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0655 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0655 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0655 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0251 | 0 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0655 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0325 | 0.1841 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0405 | 0.3805 | 0.3805 |
Treponema pallidum | flavodoxin | 0.0251 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0581 | 0.8159 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0581 | 0.8159 | 0.8159 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0655 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0405 | 0.3805 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0655 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0405 | 0.3805 | 0.2407 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0655 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0655 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.033 | 0.1964 | 0.0151 |
Giardia lamblia | Hypothetical protein | 0.0581 | 0.8159 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0581 | 0.8159 | 0.8159 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0655 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0655 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0405 | 0.3805 | 0.3805 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0581 | 0.8159 | 0.8159 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0655 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0655 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0655 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0655 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0655 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0655 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0325 | 0.1841 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate. (Class of assay: confirmatory) [Related pubchem assays: 1472, 1467 ] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.